Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response

BACKGROUND: Despite the proven efficacy of vedolizumab (VDZ) for ulcerative colitis (UC) and Crohn’s disease (CD), suboptimal response is commonly encountered. However, data regarding the effectiveness of dose intensification (by interval shortening) to achieve response are limited. OBJECTIVES: We e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Frontline Gastroenterol
Autori principali: Samaan, Mark A, Birdi, Siddharth, Morales, Maria Sierra, Honap, Sailish, Tamilarasan, Aravind Gokul, Cunningham, Georgina, Koumoutsos, Ioannis, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H C, Sanderson, Jeremy, Irving, Peter M
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2019
Soggetti:
Colorectal
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7223295/
https://ncbi.nlm.nih.gov/pubmed/32419909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/flgastro-2019-101259
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi